PL1651248T3 - Doustnie dawkowana kompozycja farmaceutyczna zawierająca środek dostarczający w postaci mikronizowanej - Google Patents

Doustnie dawkowana kompozycja farmaceutyczna zawierająca środek dostarczający w postaci mikronizowanej

Info

Publication number
PL1651248T3
PL1651248T3 PL04740863T PL04740863T PL1651248T3 PL 1651248 T3 PL1651248 T3 PL 1651248T3 PL 04740863 T PL04740863 T PL 04740863T PL 04740863 T PL04740863 T PL 04740863T PL 1651248 T3 PL1651248 T3 PL 1651248T3
Authority
PL
Poland
Prior art keywords
pharmaceutical compositions
delivery agent
pharmacologically active
micronized form
orally dosed
Prior art date
Application number
PL04740863T
Other languages
English (en)
Inventor
Shoufeng Li
Anasuya Ashok Ghosh
Simon David Bateman
Moise Azria
Alan Edward Royce
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL1651248T3 publication Critical patent/PL1651248T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Permanent Magnet Type Synchronous Machine (AREA)
PL04740863T 2003-07-11 2004-07-09 Doustnie dawkowana kompozycja farmaceutyczna zawierająca środek dostarczający w postaci mikronizowanej PL1651248T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48649503P 2003-07-11 2003-07-11
PCT/EP2004/007584 WO2005004900A1 (en) 2003-07-11 2004-07-09 Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
EP04740863A EP1651248B1 (en) 2003-07-11 2004-07-09 Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form

Publications (1)

Publication Number Publication Date
PL1651248T3 true PL1651248T3 (pl) 2010-02-26

Family

ID=34062133

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04740863T PL1651248T3 (pl) 2003-07-11 2004-07-09 Doustnie dawkowana kompozycja farmaceutyczna zawierająca środek dostarczający w postaci mikronizowanej

Country Status (14)

Country Link
US (3) US20070065505A1 (pl)
EP (1) EP1651248B1 (pl)
JP (1) JP5032844B2 (pl)
CN (1) CN1809377B (pl)
AT (1) ATE442158T1 (pl)
AU (1) AU2004255458B2 (pl)
BR (1) BRPI0412458A (pl)
CA (1) CA2529604C (pl)
DE (1) DE602004023093D1 (pl)
ES (1) ES2330638T3 (pl)
MX (1) MXPA06000446A (pl)
PL (1) PL1651248T3 (pl)
PT (1) PT1651248E (pl)
WO (1) WO2005004900A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003015822A1 (en) * 2001-08-17 2003-02-27 Novartis Ag 5-cnac as oral delivery agent for parathyroid hormone fragments
JP2008509933A (ja) * 2004-08-13 2008-04-03 エミスフェアー・テクノロジーズ・インク 送達剤のマイクロ粒子またはナノ粒子を含む医薬製剤
AU2006292337B8 (en) 2005-09-19 2013-02-07 Emisphere Technologies, Inc. Crystalline forms of the di-sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid
GB0522566D0 (en) * 2005-11-04 2005-12-14 Novartis Ag Organic compounds
KR101524880B1 (ko) * 2006-08-31 2015-06-01 노파르티스 아게 Ｈｇｈ를 포함하는 경구 전달용 제약 조성물
AR062925A1 (es) * 2006-09-22 2008-12-17 Novartis Ag Metodo para fabricar tabletas que contienen agentes farmacologicamente activos
WO2009059188A1 (en) * 2007-11-02 2009-05-07 Emisphere Technologies, Inc. Method of treating vitamin b12 deficiency
KR20130026429A (ko) * 2010-02-24 2013-03-13 에미스페어 테크놀로지스, 인코포레이티드 경구 ｂ12 치료요법
MX345501B (es) 2010-12-16 2017-02-02 Novo Nordisk As Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico.
KR101972836B1 (ko) 2011-04-12 2019-04-29 노보 노르디스크 에이/에스 이중 아실화된 ｇｌｐ-1 유도체
WO2013139695A1 (en) 2012-03-22 2013-09-26 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
HRP20190489T1 (hr) 2012-03-22 2019-05-03 Novo Nordisk A/S Pripravci koji sadrže sredstvo za unošenje i njihova priprava
EP2827885B1 (en) 2012-03-22 2018-08-15 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
US9993430B2 (en) 2012-06-20 2018-06-12 Novo Nordisk A/S Tablet formulation comprising semaglutide and a delivery agent
SMT201800492T1 (it) 2013-05-02 2018-11-09 Novo Nordisk As Dosaggio orale di composti di glp-1
CN104095828A (zh) * 2014-07-29 2014-10-15 中国药科大学 一种降钙素口服肠溶组合物及其制备方法
EP4299118A3 (en) 2018-02-02 2024-04-10 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
CR20230308A (es) 2020-12-11 2023-09-08 Civi Biopharma Inc Entrega oral de conjugados antisentido que tienen por blanco a pcsk9
CR20230471A (es) 2021-04-22 2023-11-01 Civi Biopharma Inc Administración oral de oligonucleótidos

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US6413546B1 (en) * 1999-03-18 2002-07-02 Indena, S.P.A. Tablets incorporating isoflavone plant extracts and methods of manufacturing them
NZ534409A (en) 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US6544553B1 (en) * 1999-12-28 2003-04-08 Watson Pharmaceuticals, Inc. Dosage forms and methods for oral delivery of progesterone
SK285128B6 (sk) * 1999-12-28 2006-07-07 Zentiva, A. S. Liečivý prípravok s riadeným uvoľňovaním obsahujúci tramadol hydrochlorid a spôsob jeho prípravy
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents

Also Published As

Publication number Publication date
DE602004023093D1 (de) 2009-10-22
HK1089950A1 (en) 2006-12-15
JP2009513528A (ja) 2009-04-02
US8435946B2 (en) 2013-05-07
ES2330638T3 (es) 2009-12-14
CA2529604A1 (en) 2005-01-20
US20130230593A1 (en) 2013-09-05
CN1809377A (zh) 2006-07-26
AU2004255458A1 (en) 2005-01-20
WO2005004900A1 (en) 2005-01-20
BRPI0412458A (pt) 2006-10-17
EP1651248B1 (en) 2009-09-09
JP5032844B2 (ja) 2012-09-26
US8748383B2 (en) 2014-06-10
ATE442158T1 (de) 2009-09-15
CA2529604C (en) 2012-05-08
US20080234179A1 (en) 2008-09-25
CN1809377B (zh) 2010-08-04
EP1651248A1 (en) 2006-05-03
US20070065505A1 (en) 2007-03-22
PT1651248E (pt) 2009-11-10
AU2004255458B2 (en) 2007-09-13
MXPA06000446A (es) 2006-04-07

Similar Documents

Publication Publication Date Title
AU3454702A (en) Pharmaceutical compositions for the oral delivery of pharmacologically active agents
PT1651248E (pt) Composições farmacêuticas para dose oral compreendendo um agente de administração na forma micronizada
WO2008021088A3 (en) Salicylanilides enhance oral delivery of therapeutic peptides
GEP20074231B (en) Calcitonin gene related peptide receptor antagonists
TWI366460B (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
GEP20074047B (en) Pramipexole once-daily dosage form
PT1401501E (pt) Composicoes farmaceuticas orais com libertacao modificada do ingrediente activo
AR033711A1 (es) Composiciones farmaceuticas
TW200517106A (en) Sustained release pharmaceutical compositions
MXPA05007609A (es) Antagonista de un receptor sensible al calcio.
MX2007015480A (es) Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada.
ZA200709788B (en) Cannabinold active pharmaceutical ingredient for Improved dosage forms
GB0304636D0 (en) Pharmaceutical composition for nasal delivery
EP1755633A4 (en) ORAL ADMINISTRATION OF PEPTIDE PHARMACEUTICAL COMPOSITIONS
EA200600953A1 (ru) Дозированные формы торсемида пролонгированного высвобождения
BRPI0412364A (pt) composição farmacêutica sólida, compreendendo amisulpride
WO2007011958A3 (en) Intraoral dosage forms of glucagon
ATE460934T1 (de) Pharmazeutische zubereitungen von ciprofloxacin
WO2005062722A3 (en) Fexofenadine containing pharmaceutical formulation
WO2007035816A3 (en) Paroxetine compositions
SI1653963T1 (sl) Farmacevtski sestavek piribedila za nazalno aplikacijo
HU0500270D0 (en) Pharmacologically active peptide derivatives, process for their preparation and pharmaceutical compositions containing the same
WO2008035172A3 (en) Pharmaceutical compositions containing desmopressin
TNSN06299A1 (en) Oral matrix formulations comprising licarbazepine
UY27122A1 (es) Una composición farmacéutica que comprende de 2 a 4 mg de 5-(a-(2-(n-metil-n-(2-piridil)amino)etoxi)bencil)tiazolidin-2,4-diona